March 1, 2019
Astellas Pharma said on February 28 that the European Medicines Agency has accepted for review a marketing authorization application for its acute myeloid leukemia (AML) treatment Xospata (gilteritinib). With the drug put on the agency’s accelerated path, it could land...read more